It’s something that many of us reckon with: the sense that we’re not quite as sharp as we once were. I recently turned 42. Having lost my grandfather to Alzheimer’s, and with my mom suffering...

The addition of the antitumor medication masitinib to standard of care significantly slowed cognitive deterioration and improved overall functioning for patients with mild to moderate Alzheimer’s...

Plasma biomarkers such as amyloid-beta 40 and 42, phosphorylated tau 181 and 217, and neurofilament light hold great promise for diagnosing and determining a prognosis for Alzheimer’s disease. Such...

An expert panel has released the first recommendations on the appropriate use of aducanumab (Aduhelm), the controversial anti-amyloid drug that was approved by the US Food and Drug Administration (FDA)...

An influential, independent panel unanimously voted that aducanumab (Aduhelm) offers no benefit for patients with Alzheimer’s disease (AD), adding to growing opposition from medical experts to the...

Over recent years, the retina has established its position as one of the most promising biomarkers for the early diagnosis of Alzheimer's. Moving on from the debate as to the retina becoming thinner...

Amid significant controversy, the US Food and Drug Administration (FDA) last week approved the antiamyloid agent aducanumab (Aduhelm) for the treatment of Alzheimer’s disease, disregarding the recommendation...

Alzheimer's disease (AD) is a form of progressive dementia interfering with daily living. It is caused by the decline in the number of brain cells resulting in the deterioration of our mental abilities. One...

Higher levels of physical activity at midlife are not linked to more positive cognitive outcomes, new research suggests. Results from a cohort study of more than 1700 women showed no significant association...

It’s the national record no one is celebrating: The American COVID-19 death toll has crossed the 500,000 mark. The novel coronavirus is now the third leading cause of death in the U.S....